| dc.description.abstract | Skin infections are a major public health concern for domesticated animals used in
agriculture worldwide and people in developed countries. Infections by bacteria and the
human immunodeficiency virus are more common in people with cutaneous illnesses.
Moreover, evidence has been linking the inflammatory mediators generated during the
host response to infection to mortality. Gram-positive and gram-negative bacteria that
cause clinical skin infections are among the most prevalent species, respectively, and
include Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli). Regardless of
the patient's age, location, or environment, these are the most common bacteria in skin
infections globally. Numerous earlier studies claimed that among the various
inflammatory symptoms that S. aureus and E. coli display include impetiginization,
abscesses, cellulitis, and wound infection. Consequently, several topical and oral
medicines were released to block the inflammation issue of bacteria. Additionally, these
bacteria are immune to recognized drugs due to their altered nature. Therefore, the next
generation of antibiotics needs to have a broad spectrum of action inhibition against
both S. aureus and E. coli; however, the patient will suffer numerous side effects if
used. Hence, in this study, vitamin C will be encapsulated in chitosan nanoparticles
(CSNPs-VC) that, with expectations, the antibacterial of chitosan and antiinflammatory VC would be greatly enhanced when given by topical administration of
CSNPs-VC. In addition, the CSNPs-VC will be loaded in poly(vinyl alcohol) (PVA) to
preserve the activity of CSNPs-VC and control drug release. Oxidation is one of the
inflammatory responses, so there are DPPH radicals scavenging test, hydroxyl
scavenging test, and the regulation of reactive oxygen species (ROS) and nitric oxide
(NO) produced from lipopolysaccharide to evaluate the anti-inflammation and antioxidant characteristic of CSNPs-VC. Plus, the agar diffusion test will be performed to
evaluate the CSNPs-VC antibacterial activity. According to the findings of this study,
PVA load CSNPs-VC is a promising nanogel that has great promise for the treatment
of inflammation and antibacteria, which are more benign than usual antibiotics that
resist S.aureus and E.coli on the market. | en_US |
